Navigation Links
Haemacure Reports on Financing Progress and Second Quarter Results
Date:6/2/2008

HAE:TSX

MONTREAL, June 2 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, provides financing update and reports on second quarter results.

Financing

As a result of the commitments Haemacure has received to-date from key shareholders to exercise their Series B warrants, the Corporation is well positioned to meet its objective of commencing the fibrin sealant pivotal Phase II/Phase III clinical trials. The Corporation remains on schedule and on budget with the construction of its manufacturing facility.

"We are very appreciative and encouraged by the strong support we have received from our major shareholders, Firebird Management and Pinetree Capital, as demonstrated through the exercise of their Series B warrants." said Joseph Galli, Chairman and CEO of Haemacure. "This support, coupled with the recent addition of Reinaldo Diaz to our Board of Directors and the hiring of senior managers at our facility, are elements of our value creation strategy that will make Haemacure a significant player on the global scale." concluded Mr. Galli.

Second Quarter Results

Revenues amounted to $28,368, as compared to $24,757 for the same quarter last year. Revenues are exclusively derived from the sale of legacy fibrin sealant application devices. Operating expenses amounted to $2.5 million, as compared to $1.3 million for the same quarter last year. The increase is mainly related to the hiring of personnel, consulting expenses, supplies for the laboratory and the manufacturing facility and unusual charges. The consolidated net loss for the quarter amounted to $2.5 million, or $0.02 per share, as compared to $1.3 million, or $0.01 per share, for the same quarter last year.

Financial Position

Cash, cash equivalents and temporary investments amounted to $3.6 million as of April 30, 2008, as compared to $7.6 million as at October 31, 2007.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medecine, drug delivery and combination with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one if its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. Haemacure disclaims any intention or obligation to update these statements.

Financial Highlights

(unaudited)

Quarters ended

April 30, 2008 April 30, 2007

-------------- --------------

Sales $28,368 $24,757

Gross profit $15,825 $11,725

Gross margin 56% 47%

General and administrative expenses $1,327,551 $1,177,120

Research and development expenses $668,452 $205,224

Other expenses $468,824 -

Total expenses $2,520,807 $1,313,800

Net loss $(2,504,982) $(1,302,075)

Loss per share $(0.02) $(0.01)

Weighted average number of shares

outstanding 163,800,917 163,800,917

As at As at

April 30, 2008 October 31, 2007

-------------- ----------------

Cash and cash equivalents $919,364 $3,591,883

Temporary investment $2,657,716 $4,011,200

Total assets $9,582,260 $10,939,289

Shareholders' equity $5,984,485 $9,226,329


'/>"/>
SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Haemacure to Present at Busines$ Meets Finance on May 20, 2008 at the Montreal Sheraton Centre
2. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
3. Haemacure financing receives shareholder consent - Series B Warrants are amended
4. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
5. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
6. Haemacure Reports on its annual general and special meeting of shareholders
7. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
8. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
9. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
10. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
11. Haemacure Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, ... prescribers at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , ... as the visionary leader in the training of physicians, scientists, and members of ...
(Date:3/29/2017)... ... 29, 2017 , ... The Wall Centre Dental team is ... from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain veneers, ... esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton Reskovich ...
(Date:3/29/2017)... ... 2017 , ... Patients interested in receiving quick and effective ... Cameron, with or without a referral. The FASTBRACES system is valued for its ... patient’s case, treatment with the FASTBRACES system could be completed in 120 days ...
(Date:3/29/2017)... Mich. (PRWEB) , ... March ... ... and Manufacturer Alliance (GRMA) is growing as it continues developing an ANSI-approved, ... supplement industry. The organization, which plans to publish the first ANSI-approved GMP ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, ... diagramming network and data center assets and audio-video devices has recently updated its ... equipment shapes for free and download shapes and stencils from http://www.VisioStencils.com. ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... 29, 2017  Maxor National Pharmacy Services, LLC ("Maxor"), ... has named Leah Bailey as General Counsel.  Bailey ... the company. With more than 13 years ... years focused on health care, Bailey joins the Maxor ... Prime, Bailey advised the PBM, Specialty, and Mail Order ...
(Date:3/29/2017)... 2017 Varian Medical Systems (NYSE: VAR ... second quarter of fiscal year 2017 following the close of ... will be followed by a teleconference available to all interested ... link to the conference call webcast will be available on ... teleconference call and replay: ...
(Date:3/29/2017)...  Spiral Therapeutics, Inc. today announced the signature ... for the worldwide exclusive rights to Bionure,s lead ... of otolaryngology for aggregate payments of up to ... provides Spiral with the option to license two ... Under the terms of the agreement, Spiral will ...
Breaking Medicine Technology: